Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin

Journal of Bacteriology

Volumn 185, Issue 15, 2003, Pages 4638-4643

  Mongodin, Emmanuel ^a,c   Finan, Jon ^a   Climo, Michael W ^a,b   Rosato, Adriana ^a   Gill, Steven ^c   Archer, Gordon L ^a,d  

^a Department of Medicine ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c J CRAIG VENTER INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; TRANSCRIPTOME; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL METABOLISM; BACTERIUM ISOLATE; BACTERIUM MUTANT; CELL ORGANELLE; DNA MICROARRAY; ENERGY METABOLISM; GENETIC TRANSCRIPTION; MICROARRAY TRANSCRIPTION ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN HIGHLY RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE RESISTANCE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION, GENETIC; VANCOMYCIN; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); POSIBACTERIA; PROKARYOTA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0038781384     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.185.15.4638-4643.2003     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. 2000. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. JAMA 283:597-598.
2. Centers for Disease Control and Prevention. 2000. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. Morb. Mortal. Wkly. Rep. 48:1165-1167.
3. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766.
4. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
5. Cui, L., H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285.
6. Finan, J. E., G. L. Archer, M. J. Pucci, and M. W. Climo. 2001. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:3070-3075.
7. Josefsson, E., K. W. McCrea, D. Ni Eidhin, D. O'Connell, J. Cox, M. Hook, and T. J. Foster. 1998. Three new members of the serine-aspartate repeat protein multigene family of Staphylococcus aureus. Microbiology 144:3387-3395.
8. McGahee, W., and F. D. Lowy. 2000. Staphylococcal infections in the intensive care unit. Semin. Respir. Infect. 15:308-313.
9. Moreira, B., S. Boyle-Vavra, B. L. deJonge, and R. S. Daum. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.
10. Pfeltz, R. F., V. K. Singh, J. L. Schmidt, M. A. Batten, C. S. Baranyk, M. J. Nadakavukaren, R. K. Jayaswal, and B. J. Wilkinson. 2000. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother. 44:294-303.
11. Rosato, A. E., W. A. Craig, and G. L. Archer. 2003. Quantitation of mecA transcription among oxacillin-resistant Staphylococcus aureus clinical isolates. J. Bacteriol. 185:3446-3452.
12. Ruiz, M. E., I. C. Guerrero, and C. U. Tuazon. 2002. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin. Infect. Dis. 35:1018-1020.
13. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., C. Wennersten, L. Venkataraman, R. P. Novick, and H. S. Gold. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502.
14. Shin, B. S., A. Stein, and H. Zalkin. 1997. Interaction of Bacillus subtilis purine repressor with DNA. J. Bacteriol. 179:7394-7402.
15. Sieradzki, K., M. G. Pinho, and A. Tomasz. 1999. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J. Biol. Chem. 274:18942-18946.
16. Sieradzki, K., and A. Tomasz. 1999. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J. Bacteriol. 181:7566-7570.
17. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
18. Strandén, A. M., K. Ehlert, H. Labischinski, and B. Berger-Bächi. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:9-16.
19. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98:5116-5121.
20. Weng, M., and H. Zalkin. 2000. Mutations in the Bacillus subtilis purine repressor that perturb PRPP effector function in vitro and in vivo. Curr. Microbiol. 41:56-59.